Jamax contains the active substance selegeline and belongs to the group of antiparkinsonian medicinal products.
Jamax is indicated for the treatment of Parkinson’s disease and symptomatic parkinsonism, alone or in combination with levodopa (another medicine used to treat Parkinson’s disease), with or without a peripheral enzyme inhibitor. In the early stages of Parkinson’s disease, Jamax can be used to delay the start of treatment with levodopa (with or without an enzyme inhibitor).
Upon treatment with Jamax early or moderate stage of the disease is achieved good results.
In the late stages of Parkinson’s disease, taking Jamax may increase the therapeutic effect of levodopa.
Subject to medical prescription.
Concentration and pharmaceutical form: 5 mg tablets